Muscular atrophy of caveolin-3-deficient mice is rescued by myostatin inhibition

Journal of Clinical Investigation

Volumn 116, Issue 11, 2006, Pages 2924-2934

  Ohsawa, Yutaka ^a   Hagiwara, Hiroki ^a   Nakatani, Masashi ^b   Yasue, Akihiro ^c   Moriyama, Keiji ^c   Murakami, Tatsufumi ^a   Tsuchida, Kunihiro ^b   Noji, Sumihare ^c   Sunada, Yoshihide ^a  

^a KAWASAKI MEDICAL SCHOOL   (Japan)

^b FUJITA HEALTH UNIVERSITY   (Japan)

^c UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CAVEOLIN 3; MYOSTATIN; MYOSTATIN RECEPTOR; PROTEIN P21; RECEPTOR; SMAD2 PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; GENE TARGETING; GENETIC CROSS; IN VIVO STUDY; MOUSE; MUSCLE ATROPHY; MUSCLE MASS; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; TRANSCRIPTION INITIATION;

ANIMALS; CAVEOLIN 3; CELL LINE; CERCOPITHECUS AETHIOPS; FEMALE; HUMANS; MALE; MICE; MICE, KNOCKOUT; MUSCLE STRENGTH; MUSCULAR ATROPHY; MUTATION; PHOSPHORYLATION; PROTEIN BINDING; RECOMBINANT FUSION PROTEINS; SIGNAL TRANSDUCTION; SMAD2 PROTEIN; TRANSCRIPTION, GENETIC; TRANSFORMING GROWTH FACTOR BETA; TRANSGENES;

EID: 33750578365     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI28520     Document Type: Article

References (44)

1. Parton, R.G. 2003. Caveolae-from ultrastructure to molecular mechanisms. Nat. Rev. Mol. Cell Biol. 4:162-167.
2. Galbiati, F., Razani, B., and Lisanti, M.P. 2001. Emerging themes in lipid rafts and caveolae. Cell. 106:403-411.
3. Couet, J., Li, S., Okamoto, T., Ikezu, T., and Lisanti, M.P. 1997. Identification of peptide and protein ligands for the caveolin-scaffolding domain. Implications for the interaction of caveolin with caveolae-associated proteins. J. Biol. Chem. 272:6525-6533.
4. Minetti, C., et al. 1998. Mutations in the caveolin-3 gene cause autosomal dominant limb-girdle muscular dystrophy. Nat. Genet. 18:365-368.
5. Sunada, Y., et al. 2001. Transgenic mice expressing mutant caveolin-3 show severe myopathy associated with increased nNOS activity. Hum. Mol. Genet. 10:173-178.
6. Smythe, G.M., Eby, J.C., Disatnik, M.H., and Rando, T.M. 2003. A caveolin-3 mutant that causes limb girdle muscular dystrophy type 1C disrupts Src localization and activity and induces apoptosis in skeletal myocytes. J. Cell Sci. 116:4739-4749.
7. Hernandez-Deviez, D.J., et al. 2006. Aberrant dysferlin trafficking in cells lacking caveolin or expressing dystrophy mutants of caveolin-3. Hum. Mol. Genet. 15:129-142.
8. McPherron, A.C., Lawler, A.M., and Lee, S.-J. 1997. Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member. Nature. 387:83-90.
9. Zimmers, T.A., et al. 2002. Induction of cachexia in mice by systemically administered myostatin. Science. 296:1486-1488.
10. Reisz-Porszasz, S., et al. 2003. Lower skeletal muscle mass in male transgenic mice with muscle-specific overexpression of myostatin. Am. J. Physiol. Endocrinol. Metab. 285:E876-E888.
11. Grobet, L., et al. 2003. Modulating skeletal muscle mass by postnatal, muscle-specific inactivation of the myostatin gene. Genesis. 35:227-238.
12. Nishi, M., et al. 2002. A missense mutant myostatin causes hyperplasia without hypertrophy in the mouse muscle. Biochem. Biophys. Res. Commun. 293:247-251.
13. Thies, R.S., et al. 2001. GDF-8 propeptide binds to GDF-8 and antagonizes biological activity by inhibiting GDF-8 receptor binding. Growth Factors. 18:251-259.
14. Wolfman, N.M., et al. 2003. Activation of latent myostatin by the BMP-1/tolloid family of metalloproteinases. Proc. Natl. Acad. Sci. U. S. A. 100:15842-15846.
15. Yang, J., et al. 2001. Expression of myostatin pro domain results in muscular transgenic mice. Mol. Reprod. Dev. 60:351-361.
16. Pirottin, D., et al. 2005. Transgenic engineering of male-specific muscular hypertrophy. Proc. Natl. Acad. Sci. U. S. A. 102:6413-6418.
17. Yang, J., and Zhao, B. 2006. Postnatal expression of myostatin propeptide cDNA maintained high muscle growth and normal adipose tissue mass in transgenic mice fed a high-fat diet. Mol. Reprod. Dev. 73:462-469.
18. Massague, J. 1998. TGF-beta signal transduction. Annu. Rev. Biochem. 67:753-791.
19. Lee, S.-J., and McPherron, A.C. 2001. Regulation of myostatin activity and muscle growth. Proc. Natl. Acad. Sci. U. S. A. 98:9306-9311.
20. Rebbapragada, A., Benchabane, H., Wrana, J.L., Celeste, A.J., and Attisano, L. 2003. Myostatin signals through a transforming growth factor beta-like signaling pathway to block adipogenesis. Mol. Cell. Biol. 23:7230-7242.
21. Rios, R., Fernandez-Nocelos, S., Carneiro, I., Arce, V.M., and Devesa, J. 2004. Differential response to exogenous and endogenous myostatin in myoblasts suggests that myostatin acts as an autocrine factor in vivo. Endocrinology. 145:2795-2803.
22. Thomas, M., et al. 2000. Myostatin, a negative regulator of muscle growth, functions by inhibiting myoblast proliferation. J. Biol. Chem. 275:40235-40243.
23. Razani, B., et al. 2001. Caveolin-1 regulates transforming growth factor (TGF)-beta/SMAD signaling through an interaction with the TGF-beta type I receptor. J. Biol. Chem. 276:6727-6738.
24. Lee, S.-J., et al. 2005. Regulation of muscle growth by multiple ligands signaling through activin type II receptors. Proc. Natl. Acad. Sci. U. S. A. 102:18117-18122.
25. Jonk, L.J., Itoh, S., Heldin, C.-H., ten Dijke, P., and Kruijer, W. 1998. Identification and functional characterization of a Smad binding elements (SBE) in the JunB promoter that acts as a transforming growth factor-beta, activin, and bone morphogenetic protein-inducible enhancer. J. Biol. Chem. 273:21145-21152.
26. Hill, J.J., et al. 2002. The myostatin propeptide and the follistatin-related gene are inhibitory binding proteins of myostatin in normal serum. J. Biol. Chem. 277:40735-40741.
27. Schuelke, M., et al. 2004. Myostatin mutation associated with gross muscle hypertrophy in a child. N. Engl. J. Med. 350:2682-2688.
28. Campion, D.R. 1984. The muscle satellite cell: a review. Int. Rev. Cytol. 87:225-251.
29. Feng, X.-H., and Derynck, R.A. 1997. A kinase subdomain of transforming growth factor-beta (TGF-beta) type I receptor determines the TGF-beta intracellular signaling specificity. EMBO J. 16:3912-3923.
30. Di Guglielmo, G.M., Le Roy, C., Goodfellow, A.F., and Wrana, J.L. 2003. Distinct endocytic pathways regulate TGF-beta receptor signalling and turnover. Nat. Cell Biol. 5:410-421.
31. Le Roy, C., and Wrana, J.L. 2005. Clathrin- and non-clathrin-mediated endocytic regulation of cell signalling. Nat. Rev. Mol. Cell Biol. 6:112-126.
32. DiMario, J.X., Uzman, A., and Strohman, R.C. 1991. Fiber regeneration is not persistent in dystrophic (MDX) mouse skeletal muscle. Dev. Biol. 148:314-321.
33. Pastoret, C., and Sebille, A. 1993. Further aspects of muscular dystrophy in mdx mice. Neuromuscul. Disord. 3:471-475.
34. Oh, S.P., et al. 2002. Activin type IIA and IIB receptors mediate Gdf11 signaling in axial vertebral patterning. Genes Dev. 16:2749-2754.
35. De Caestecker, M. 2004. The transforming growth factor-beta superfamily of receptors. Cytokine Growth Factor Rev. 15:1-11.
36. Sotgia, F., et al. 2006. Caveolin-1 deficiency (-/-) conveys premalignant alterations in mammary epithelia, with abnormal lumen formation, growth factor independence, and cell invasiveness. Am. J. Pathol. 168:292-309.
37. Bogdanovich, S., et al. 2002. Functional improvement of dystrophic muscle by myostatin blockade. Nature. 420:418-421.
38. Bogdanovich, S., Perkins, K.J., Krag, T.O.B., Whittemore, L.-A., and Khurana, T.S. 2005. Myostatin propeptide-mediated amelioration of dystrophic pathology. FASEB J. 19:543-549.
39. Li, Z.F., Shelton, G.D., and Engvall, E. 2005. Elimination of myostatin does not combat muscular dystrophy in dy mice but increase postnatal lethality. Am. J. Pathol. 166:491-495.
40. Narita, T., et al. 2005. Wnt10a is involved in AER formation during chick limb development. Dev. Dyn. 233:282-287.
41. Kawabata, M., Inoue, H., Hanyu, A., Imamura, T., and Miyazono, K. 1998. Smad proteins exist as monomers in vivo and undergo homo- and hetero-oligomerization upon activation by serine/threonine kinase receptors. EMBO J. 17:4056-4065.
42. Murakami, G., Watabe, T., Takaoka, K., Miyazono, K., and Imamura, T. 2003. Cooperative inhibition of bone morphogenetic protein signaling by Smurf1 and inhibitory Smads. Mol. Biol. Cell. 14:2809-2817.
43. Funaba, M., et al. 2003. Transcriptional activation of mouse mast cell Protease-7 by activin and transforming growth factor-beta is inhibited by microphthalmia-associated transcription factor. J. Biol. Chem. 278:52032-52041.
44. Sasaoka, T., et al. 2003. Pathological analysis of muscle hypertrophy and degeneration in muscular dystrophy in gamma-sarcoglycan-deficient mice. Neuromuscul. Disord. 13:193-206.